Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
There is no official dose since it is not approved - start conservative and increase gradually
After transitioning to semaglutide 2.4 mg weekly (the Wegovy dose) , she developed skin dysesthesia within a few weeks
Use: In combination with a reduced calorie diet and increased physical activity, for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) Usual Pediatric Dose for Weight Loss 12 YEARS AND OLDER: Wegovy Injection: Initial dose (weeks 1 through 4): 0.25 mg subcutaneously once a week Dose escalation: Weeks 5 through 8: 0.5 mg subcutaneously once a week Weeks 9 through 12: 1 mg subcutaneously once a week Weeks 13 through 16: 1.7 mg subcutaneously once a week Alternatively: 1.7 mg subcutaneously once a week Comments: The recommended maintenance dose is 2.4 mg
Safety exclusions, drug interactions, and tolerability history often narrow the decision more than headline trial results
Hershey Medical Center Lead Sponsor National Institute on Drug Abuse (NIDA) Collaborator University of Maryland Collaborator New York University Collaborator Stanley Street Treatment and Resources (SSTAR) Collaborator Published Research Related to This Trial Citations Semaglutide and Opioid Overdose Risk in Patients With
US$ 22.71
US$ 26.25
US$ 21.03
US$ 27.91
